<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypersensitivity reactions to insulins</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypersensitivity reactions to insulins</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypersensitivity reactions to insulins</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lucie Heinzerling, MD, PhD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H453386029"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Several types of hypersensitivity reactions to insulin preparations have been described. These reactions may be caused by the insulin itself or by additives within the preparation. Hypersensitivity reactions to insulin are rare with human insulins and insulin analogs. However, some types of reactions are serious, and even life threatening, and may have a significant detrimental impact on diabetes management. Evaluation requires close collaboration between endocrinology and allergy experts.</p><p>The clinical manifestations, classification, diagnosis, and management of hypersensitivity reactions to insulin preparations are discussed in this topic review. Other adverse effects of insulin therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'Safety'</a>.)</p><p class="headingAnchor" id="H29781079"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Hypersensitivity to insulin or insulin analogs can occur in all age groups and in patients with either type 1 or type 2 diabetes and includes local reactions, systemic reactions, and, rarely, true allergic reactions. Although comprehensive epidemiologic studies are lacking, estimates of incidence range from 0.1 to 7.1 percent of patients [<a href="#rid1">1-3</a>], with injection-site reactions in 1.4 percent and insulin-related allergic events in 0.6 percent of patients [<a href="#rid4">4</a>]. Insulin hypersensitivity is rare with the preparations in use today, although it was more common when relatively impure and heterologous porcine and bovine insulins were widely used as these are far more immunogenic. The progressive improvement in purification of nonhuman insulins, use of single-animal species insulins, and the nearly universal adoption of highly purified human insulins beginning in the 1980s all contributed to the reduction in injection-site and systemic allergic reactions to insulin.</p><p>When encountering a patient who appears to be reacting to insulin, it is important to understand the other conditions that can mimic insulin hypersensitivity. A retrospective study of 22 patients with suspected insulin allergy determined that 59 percent of patients did not have an allergic cause of their symptoms [<a href="#rid5">5</a>]. This is in keeping with the author's experience. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1900559756"><span class="h2">Risk factors for immediate allergy</span><span class="headingEndMark"> — </span>Aside from the use of heterologous porcine and bovine insulins, risk factors for immediate insulin allergy are largely unknown. Possible risk factors include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA haplotype</strong> – In a small case-control study, the frequency of human leukocyte antigen (HLA) A2 among 10 insulin-allergic patients was 80 percent compared with 46 percent in 21 insulin-treated controls without allergy [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recent COVID-19 or vaccination against COVID-19</strong> – Cases of insulin allergy occurring after coronavirus disease 2019 (COVID-19) infection [<a href="#rid7">7</a>] and COVID-19 vaccination [<a href="#rid8">8</a>] have been described. Theories about possible inciting factors include the proinflammatory state (after infection) or the presence of fatty acid moieties in both the messenger ribonucleic acid (mRNA) of the vaccine and in insulin (after vaccination).</p><p></p><p class="headingAnchor" id="H25138030"><span class="h1">TYPES OF HYPERSENSITIVITY REACTIONS</span><span class="headingEndMark"> — </span>Hypersensitivity reactions to insulin preparations may be divided into "immediate" and "delayed," based upon how quickly signs and symptoms appear. However, it is not always possible to make this distinction.</p><p class="headingAnchor" id="H815357"><span class="h2">Immediate</span><span class="headingEndMark"> — </span>Immediate hypersensitivity reactions to insulin (or an additive in the insulin preparation) generally develop within one hour after an injection, although the symptoms often appear much more rapidly (sometimes within seconds) [<a href="#rid9">9</a>]. Immediate reactions range from local skin reactions to systemic reactions. The severity of immediate reactions can also vary somewhat from injection to injection, which is true of anaphylaxis caused by any allergen. Cofactors, such as exercise or concomitant infection, can accentuate allergic symptoms or lower the patient's threshold for reacting. Immediate reactions tend to worsen over time and must be actively evaluated and managed in patients who will require ongoing insulin therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local immediate reactions</strong> – Local skin reactions present as rapidly developing pruritic erythema and/or wheal at the injection site [<a href="#rid5">5</a>]. Sometimes local symptoms increase in intensity over time (days to weeks), ultimately culminating in systemic reactions. This phenomenon has also been described with allergic reactions to other allergens, in which symptoms are initially limited to the skin but then evolve to affect the respiratory and/or gastrointestinal tract, eventually resulting in full anaphylaxis [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic immediate reactions</strong> – Systemic reactions may present with generalized urticaria, pruritus (especially of the palms and soles), and angioedema, although a wide range of symptoms are possible (<a class="graphic graphic_table graphicRef58836" href="/d/graphic/58836.html" rel="external">table 1</a>) [<a href="#rid11">11,12</a>]. Sometimes previous injection sites will react (ie, become erythematous) simultaneously [<a href="#rid13">13,14</a>]. Nausea, diarrhea, confusion, tremor, blurry vision, and diplopia have been reported with anaphylaxis to insulin, although these symptoms are not typical of drug-induced anaphylaxis. Cases of severe anaphylaxis have been reported in the past, including fatalities, but not with more purified forms of insulin [<a href="#rid15">15-18</a>].</p><p></p><p>Immediate reactions to insulin preparations are believed to be immunoglobulin E (IgE) mediated, type I immunologic reactions to insulin or to an additive (<a class="graphic graphic_table graphicRef80466 graphicRef91420" href="/d/graphic/80466.html" rel="external">table 2A-B</a>). In type I drug allergy, sensitization to the antigen (drug) develops in susceptible individuals prior to the initial allergic reaction. Sensitization refers to the formation of drug-specific IgE molecules and binding of these molecules to high-affinity IgE receptors on mast cells and basophils. However, not all sensitized individuals develop allergic symptoms, and patients treated with human insulin may develop insulin-specific IgE antibodies within the first few months of therapy and remain asymptomatic [<a href="#rid19">19</a>]. Once sensitization has occurred, reexposure to the drug can lead to cross-linking of IgE on the surface of mast cells and basophils and subsequent release of histamine and other inflammatory mediators. Histamine specifically induces vasodilatation, an increase in vessel permeability, and pruritus. In the past, with beef or pork insulins, a typical scenario leading to IgE-mediated insulin allergy was the onset of urticaria, stopping of insulin for weeks or months, and then the development of anaphylaxis when insulin was resumed. In the case of modern insulins, it is not known if interruptions in therapy increase the risk of immediate reactions. Since continuous administration desensitizes at least to some extent, interruption for several days or weeks due to symptoms and subsequent reinduction could lead to more severe reactions. (See  <a class="medical medical_review" href="/d/html/2072.html" rel="external">"Drug allergy: Pathogenesis", section on 'Type I (IgE-mediated)'</a>.)</p><p>Immediate reactions to human insulins typically develop months to years after beginning injection therapy with a specific insulin preparation [<a href="#rid20">20</a>]. However, there are case reports of immediate reactions developing upon the patient's first few injections or in response to an insulin to which the patient had no known previous exposure [<a href="#rid18">18,21,22</a>]. In these unusual cases, it is possible that the culprit antigen is similar to another antigen to which the patient had been previously exposed.</p><p class="headingAnchor" id="H815364"><span class="h2">Delayed</span><span class="headingEndMark"> — </span>Delayed reactions develop later than one hour after injection, and, in most cases, they start several hours to one or two days later. Delayed reactions are usually cutaneous, transient, and resolve spontaneously within a few weeks with continuation of therapy. If they persist, they can be evaluated on a nonurgent basis. (See <a class="local">'When to refer'</a> below.)</p><p>At least two distinct types of delayed reactions have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>Induration and subcutaneous nodules at the site of injections, which are most likely a form of type III reaction (immune complex-mediated reactions). These lesions may be painful and can persist for weeks, although most will eventually resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eczematous skin changes or exanthema at the site of injections, which are likely type IV reactions (ie, contact dermatitis). They can be pruritic.</p><p></p><p class="headingAnchor" id="H3806173949"><span class="h1">INITIAL ASSESSMENT</span></p><p class="headingAnchor" id="H3747588163"><span class="h2">Clinical history</span><span class="headingEndMark"> — </span>The history should focus on the rapidity with which the signs and symptoms develop after injection (ie, within minutes to one hour versus later) to distinguish immediate from delayed reactions, the presence or absence of systemic symptoms to judge the severity, and whether the reactions have become worse over time. Important questions in the evaluation of possible hypersensitivity reaction to insulin include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>What are the specific symptoms following insulin injections?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>How quickly do the symptoms develop with respect to each injection? Immediate reactions begin within one hour of injection for a pure insulin but may occur at the time of peak blood levels in insulins with delayed or prolonged absorption. Delayed reactions start later than one hour after injection, and, in most cases, they start several hours to one or two days later.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are the symptoms localized to the injection site, or do they affect more distant parts of the body (ie, systemic)? Does the reaction involve wheals at the injection sites that persist for less than 24 hours, or is the reaction mostly induration that persists for hours or days?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have the symptoms been observed by a clinician (or could they be)?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Are the symptoms the same after each injection, or are they variable and changing over time? If the patient initially had local reactions and now is having systemic symptoms, the possibility of impending anaphylaxis should be considered, and evaluation should be expedited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Do the symptoms sometimes occur unrelated to insulin injections? Do reactions occur only when the patient also takes a nonsteroidal antiinflammatory drug? If the patient answers affirmatively to either question, disorders such as chronic urticaria/angioedema should be considered. This is the most common alternative explanation found by allergists to whom patients with "insulin allergy" are referred. Physical exam demonstrating dermatographism can help establish this diagnosis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Which insulins were used in the past, and how well were they tolerated? If any other insulin preparations were used in the past, the additives and types of insulins should be compared. However, the clinician should be mindful that, in patients who have developed a new allergy to an insulin or additive, the fact that a preparation containing that same component was tolerated in the past does not exclude the possibility that the patient has become reactive to it since.</p><p></p><p>If other dermatologic conditions can be excluded, the clinician should attempt to categorize the reaction. Sometimes it is not clear from the patient's history or examination whether a local reaction is delayed or immediate, and, in this situation, it is prudent to evaluate for both possibilities.</p><p class="headingAnchor" id="H1827246317"><span class="h2">Physical findings</span><span class="headingEndMark"> — </span>If signs and symptoms are limited to the skin, the injection site and the rest of the integument should be carefully examined. In most cases, skin changes that are suspected to be a manifestation of insulin hypersensitivity have other causes, such as injection-site irritation or a separate dermatologic condition, such as prurigo nodularis simplex subacuta or atopic dermatitis. (See <a class="local">'Exclude injection-site irritation'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H1880279363"><span class="h2">Exclude injection-site irritation</span><span class="headingEndMark"> — </span>In most cases, localized symptoms at injection sites of human insulins are mild and are caused by irritation rather than true hypersensitivity. They can be managed by optimizing injection technique and other simple measures. A knowledgeable clinician should observe the patient's injection technique. The following measures can be helpful:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with eczematous skin changes at the site, discontinue routine use of isopropyl alcohol swabs or other irritating cleansing solutions. Use of cleaners at injection sites is not necessary. In addition, topical antiinflammatory ointments can be applied.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with induration or subcutaneous nodules, make sure to inject deeply enough, cool the site briefly before injecting, try smaller needles, and/or massage the injection site for a few moments after injecting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with localized urticaria at the site, avoid injecting where clothing or belt buckles rub against the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For any injection-site reaction, change sites regularly.</p><p></p><p>If these measures do not result in improvement, then further evaluation is appropriate. Proper insulin injection techniques are discussed separately. (See  <a class="medical medical_review" href="/d/html/1752.html" rel="external">"General principles of insulin therapy in diabetes mellitus", section on 'Injection technique'</a> and  <a class="medical medical_basics" href="/d/html/15594.html" rel="external">"Patient education: Using insulin (The Basics)", section on 'How do I give myself an insulin shot?'</a>.)</p><p class="headingAnchor" id="H2896841559"><span class="h1">DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate reactions </strong>– The diagnosis of an immediate hypersensitivity reaction to insulin is based upon a suggestive clinical history, the demonstration of IgE sensitization to insulin (using skin prick/intracutaneous testing and/or IgE immunoassays) or to an additive (very rare), and exclusion of other causes of the symptoms [<a href="#rid23">23,24</a>]. Exclusion of other causes (eg, urticaria/angioedema, other allergies) is important because skin prick/intracutaneous testing with insulins can yield false-positive results. (See <a class="local">'False-positive results'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed reactions </strong>– The diagnosis of a delayed hypersensitivity reaction to insulin is based upon a suggestive clinical history, testing that is determined by the type of delayed reaction (ie, skin testing with delayed readings or patch testing), characterization of histologic changes on skin biopsy, and exclusion of other causes.</p><p></p><p class="headingAnchor" id="H3610757688"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate </strong>– The most common disorder that mimics immediate hypersensitivity to insulin is acute or chronic urticaria [<a href="#rid5">5</a>]. However, careful questioning and/or the finding of dermatographism should uncover episodes of urticaria/angioedema that are intermittent or ongoing over a period of time and are only <strong>accentuated</strong> by insulin injections. Patients should be questioned for other triggers for urticaria, such as intake of nonsteroidal antiinflammatory drugs, bacterial or viral infections, dietary factors, or physical factors (heat, pressure, scratching of the skin). (See  <a class="medical medical_review" href="/d/html/8108.html" rel="external">"Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history", section on 'Aggravating factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed </strong>– There are several skin diseases that have been mistaken for delayed insulin hypersensitivity, including prurigo nodularis simplex subacuta, exacerbation of atopic dermatitis, psoriasis, and contact dermatitis unrelated to insulin preparations [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/13667.html" rel="external">"Prurigo nodularis"</a> and  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a>.)</p><p></p><p class="bulletIndent1">Localized lipodystrophies, or changes in subcutaneous fatty tissue at injection sites, are not usually confused with hypersensitivity. Lipoatrophy (loss of fatty tissue) is believed to be an autoimmune phenomenon that can be aesthetically upsetting but is rare with modern insulins [<a href="#rid25">25,26</a>]. Lipohypertrophy is a consequence of repeated injections at a specific site and results from insulin's known local effects on adipose tissue. It is associated with a decreased response to insulin and fluctuating blood glucose levels [<a href="#rid27">27,28</a>]. Patients should be advised not to inject in areas of lipohypertrophy.</p><p></p><p class="headingAnchor" id="H3074148119"><span class="h1">INITIAL INTERVENTIONS</span></p><p class="headingAnchor" id="H131982170"><span class="h2">For immediate reactions</span></p><p class="headingAnchor" id="H1452977215"><span class="h3">Anaphylaxis</span><span class="headingEndMark"> — </span>Anaphylaxis to human insulin, although rare, is a medical emergency. It is important to recognize early symptoms of potentially severe immediate reactions, like pruritus of palms and soles, hoarseness or dyspnea, or a decrease of blood pressure, since patients with these symptoms require close monitoring in a supervised setting. Patients who have experienced anaphylaxis or have symptoms of impending anaphylaxis should be admitted to the hospital urgently for emergency care and for multidisciplinary management. Stopping insulin therapy in patients who require it can result in ketoacidosis [<a href="#rid20">20</a>]. (See <a class="local">'Referral for allergy evaluation'</a> below.)</p><p class="headingAnchor" id="H3898613999"><span class="h3">Less severe reactions</span><span class="headingEndMark"> — </span>Mild-to-moderate immediate reactions, such as localized hives or mild generalized hives and angioedema, can be managed with symptomatic therapy while the patient is referred for allergy evaluation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral antihistamines</strong> can be helpful for patients with urticaria or angioedema [<a href="#rid29">29</a>]. Drugs and doses are similar to those used for chronic urticaria, which are reviewed separately. (See  <a class="medical medical_review" href="/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Stepwise approach to treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> might be necessary for patients with urticaria/angioedema in some cases, until the diagnosis is made and a management plan is determined. However, glucocorticoids elevate blood sugars further and complicate management, so they should be given for the shortest amount of time possible.</p><p></p><p class="headingAnchor" id="H433633716"><span class="h3">Empirically change insulin</span><span class="headingEndMark"> — </span>In patients who require continuation of insulin therapy, the clinician can choose a different insulin preparation or an insulin analog [<a href="#rid30">30-32</a>]. Insulin analogs are options for patients allergic to human insulin [<a href="#rid33">33</a>], although, if the patient has signs or symptoms of a severe systemic immediate allergic reaction, it is important to consider the additives contained in the different preparations as these are often used in both human insulin and analogs. Analogs have been implicated in immediate hypersensitivity reactions as well [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H2858602170"><span class="h3">Use a non-insulin therapy</span><span class="headingEndMark"> — </span>In patients with type 2 diabetes, there are several non-insulin therapies that could be considered. They include oral hypoglycemic agents and glucagon-like peptide. Some of them have also been implicated in allergic reactions [<a href="#rid36">36-38</a>]. In addition, patients could reduce the need for insulins by implementing lifestyle measures like weight loss. (See  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H3564733978"><span class="h2">For delayed reactions</span><span class="headingEndMark"> — </span>Because delayed reactions typically resolve with time, initial measures are intended to minimize symptoms. First, ensure that the patient is injecting deep enough into the subcutaneous layers of the skin, and evaluate for other causes of injection-site irritation. (See <a class="local">'Exclude injection-site irritation'</a> above.)</p><p>For symptomatic relief:</p><p class="bulletIndent1"><span class="glyph">●</span>Local eczematous reactions can be treated with a topical corticosteroid-containing ointment such as <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus may respond to local application of a polidocanol-containing urea cream (commercially available in Europe, Asia, and Australia but not in the United States). Oral antihistamines, such as <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a> 10 to 20 mg once or twice daily, are also helpful for pruritus [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H334579319"><span class="h1">FURTHER EVALUATION AND MANAGEMENT</span></p><p class="headingAnchor" id="H2194406283"><span class="h2">Immediate reactions</span></p><p class="headingAnchor" id="H710833"><span class="h3">Referral for allergy evaluation</span><span class="headingEndMark"> — </span>Allergy evaluation for immediate reactions to insulin preparations involves a thorough review of the insulins to which the patient has already been exposed, skin testing with insulins and additives to try to identify the culprit allergen, and in vitro testing. This evaluation is usually done by an allergy specialist.</p><p class="headingAnchor" id="H1727341915"><span class="h4">Potential allergens</span><span class="headingEndMark"> — </span>Immediate allergic reactions to insulin preparations can be elicited by the insulin itself or by additives within the insulin preparation (<a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>).</p><p class="headingAnchor" id="H3736489628"><span class="h5">Insulins</span><span class="headingEndMark"> — </span>Both human insulins (neutral protamine Hagedorn [NPH] and <a class="drug drug_general" data-topicid="9030" href="/d/drug information/9030.html" rel="external">regular insulin</a>) and insulin analogs (eg, lispro, aspart, glulisine, glargine, detemir, and degludec) can induce allergic reactions. The antigenic epitope may be a nonself-epitope, an altered self-epitope, or an epitope generated by alternate protein folding that can occur during production or purification of insulin preparations. In theory, the degradation of insulin in the subcutaneous depot (eg, by proteases) could expose other epitopes. In most cases, the antigenic epitope is thought to be a determinant unique to recombinant proteins, which have different tertiary structures [<a href="#rid39">39</a>], or a determinant on one of the nonprotein components [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H2257387330"><span class="h5">Protamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9831" href="/d/drug information/9831.html" rel="external">Protamine sulfate</a> is a protein isolated from fish sperm that can be complexed to insulin to delay absorption. Protamine has been implicated in immediate allergic reactions in patients with diabetes, as well as in anaphylaxis during reversal of heparin in cardiovascular procedures (<a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>) [<a href="#rid17">17,41-43</a>]. Previous exposure to protamine is a risk factor for having protamine allergy. In contrast, fish allergy and prior vasectomy have been proposed as risk factors for protamine allergy, but one prospective study found no evidence for these associations [<a href="#rid44">44</a>]. The pathogenesis of immediate reactions to protamine is not established, and both IgE-mediated and complement-mediated mechanisms have been proposed [<a href="#rid45">45</a>]. Thus, immediate-type skin testing has been successfully used to identify protamine-sensitive patients in some but not all patients [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1019661645"><span class="h5">Other additives</span><span class="headingEndMark"> — </span>Cresol compounds are preservatives present in most insulin preparations that should be considered in immediate reactions (<a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>). Latex has also been implicated in rare cases. Other additives have not been implicated in immediate reactions to insulins.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cresol</strong> – An unusual case report described a patient with pain, erythema, induration, and urticaria developing at the injection site within five minutes, followed rapidly thereafter by localized skin erosion, with positive skin testing to cresol in <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latex</strong> – Trace amounts of latex from vial membranes have been implicated in rare reports of allergic reactions to insulin preparations [<a href="#rid47">47,48</a>]. However, many vial membranes are now latex free. A careful clinical history of other latex exposures should be obtained (<a class="graphic graphic_table graphicRef63643" href="/d/graphic/63643.html" rel="external">table 3</a>). Latex allergy is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/5543.html" rel="external">"Latex allergy: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H3103825112"><span class="h4">Skin testing</span><span class="headingEndMark"> — </span>Skin testing for IgE-mediated allergy involves skin prick testing and intracutaneous (ie, intradermal) testing under close monitoring by an allergy expert [<a href="#rid49">49</a>]. Prick testing is performed initially, with appropriate positive (eg, histamine 10 mg/mL) and negative (eg, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> 0.9%) controls. Insulins are applied undiluted for prick testing. If the initial readings of the prick tests are negative, then intradermal (intracutaneous) testing is performed next, using insulin solutions that are diluted in saline 1:100 [<a href="#rid50">50</a>]. Most insulins are commercially available in a 100 unit/mL solution; a 1:100 dilution is equivalent to 1 unit/mL. Prior to undergoing skin testing for immediate reactions, patients must discontinue any antihistamines for a sufficient period of time (seven days for most agents). Other medications and factors that affect skin prick/intracutaneous test results are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease", section on 'Factors affecting results'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Prick tests are read after 15 minutes. A wheal with a diameter ≥3 mm is considered a positive reaction (<a class="graphic graphic_picture graphicRef89445" href="/d/graphic/89445.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the prick tests are negative after 15 minutes, then intradermal testing is performed. Results are measured after 15 minutes. A diameter of the wheal of ≥3 mm greater than the size of the initial injection bleb is considered as a positive reaction.</p><p></p><p>The sensitivity and specificity of the skin prick testing was 10 and 100 percent, respectively, while that of intradermal testing was 80 and 100 percent, respectively, in a case-control study that also included patients with delayed-type hypersensitivity [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H917137218"><span class="h5">Insulin preparations</span><span class="headingEndMark"> — </span>The author's approach is to perform prick testing with the following (<a class="graphic graphic_form graphicRef89388" href="/d/graphic/89388.html" rel="external">form 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The insulin(s) to which the patient reacted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All other insulins that are routinely used to determine if these would be options for the patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The additives that have been most often implicated in immediate reactions (eg, protamine, cresol, and possibly latex).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An additive-free insulin preparation, if available from the manufacturer.</p><p></p><p>However, not all of these reagents may be available in all settings, and the clinician may need to modify this approach.</p><p class="headingAnchor" id="H4133500315"><span class="h5">Protamine and other additives</span><span class="headingEndMark"> — </span>Commercial kits containing various insulin preparations and insulin additives for use in skin testing were available in some European countries in the past, although production has been discontinued in most. If a kit is not available, an insulin-diluting medium that contains the additives or a subset of them in question can be used for testing [<a href="#rid29">29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9831" href="/d/drug information/9831.html" rel="external">Protamine sulfate</a> for injection (10 mg/mL) may be diluted 30-fold to 333 micrograms/mL for <strong>prick</strong> skin testing, which is similar to the concentration in undiluted NPH insulin (350 micrograms/mL) [<a href="#rid23">23</a>]. For <strong>intraderma</strong>l testing, the testing solution should be diluted further. Initial concentrations for intradermal testing are generally 10- or 100-fold more dilute than prick testing solutions, and further dilutions are warranted for patients with anaphylaxis. One patient with anaphylaxis had a positive intradermal test to 0.03 nanograms/mL of protamine, so extreme sensitivity is possible [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin testing with cresol can be performed with a solution of 1.5 mg/mL for prick testing. Initial concentrations for intradermal testing should be 100- or 10-fold more dilute than prick testing solutions. Some manufacturers may supply solutions containing the additives that are present in the insulin preparations [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin testing to latex and/or in vitro testing for latex-specific IgE can be performed. Validated latex skin tests are not available in some countries, including the United States. (See  <a class="medical medical_review" href="/d/html/5543.html" rel="external">"Latex allergy: Epidemiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2869176289"><span class="h5">False-positive results</span><span class="headingEndMark"> — </span>Note that immediate-type skin testing must be interpreted in the context of the patient's clinical history because false-positive skin prick tests have been documented to both human insulin and protamine in subjects with diabetes without any allergic symptoms [<a href="#rid16">16,23</a>]. Because immediate insulin hypersensitivity is so rare with recombinant human insulins, it is difficult to collect enough patients to perform studies of the sensitivity and specificity of skin testing. A small study of seven patients newly treated with human insulin found that positive prick test results and low insulin-specific IgE titers developed in nearly one-third of subjects, although none had symptoms of hypersensitivity [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3845878355"><span class="h4">In vitro allergy tests</span><span class="headingEndMark"> — </span>It is the author's approach to obtain insulin-specific IgE, latex-specific IgE, and protamine-specific IgE in patients with immediate reactions [<a href="#rid51">51</a>]. Absence of measurable levels of specific IgE antibodies makes an immediate type I allergy unlikely. Delayed reactions, however, are not mediated by IgE and would not be expected to show positive insulin-specific IgE antibodies.</p><p class="bulletIndent1">In contrast to allergen-specific IgE antibodies, assessment of neutralizing immunoglobulin G (IgG) antibodies is not relevant to the diagnosis or management of insulin allergy. Neutralizing antibodies have not been shown to have an impact on long-term HbA1c or insulin requirements, as documented in a study investigating <a class="drug drug_general" data-topicid="9020" href="/d/drug information/9020.html" rel="external">insulin aspart</a> [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H1252237037"><span class="h3">Management of confirmed allergy</span><span class="headingEndMark"> — </span>Once immediate hypersensitivity has been confirmed to one preparation of insulin or to an additive, it should be carefully documented and explained to the patient. The causative allergen can be avoided by choosing a different insulin preparation suitable for the patient (<a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>) [<a href="#rid52">52,53</a>] or a non-insulin-based therapy. If no alternative preparation can be identified or the patient does not experience adequate control of blood sugars using alternative insulins, desensitization to the desired insulin can be performed. Case reports have described the use of anti-IgE therapy, pancreatic transplant, and immunosuppressants in complicated cases. (See <a class="local">'Insulin desensitization'</a> below and <a class="local">'Omalizumab and other options'</a> below.)</p><p class="headingAnchor" id="H2931823"><span class="h4">Patient education and allergy documentation</span><span class="headingEndMark"> — </span>Patients with confirmed type I allergy (eg, to insulin or protamine) must be educated about their allergy, and the allergy should be thoroughly documented in the patient's medical record. The patient should be encouraged to obtain a medical identification bracelet or other jewelry stating their allergy. In addition, the patient should be given an allergy card or letter that includes the following information:</p><p class="bulletIndent1"><span class="glyph">●</span>What type of allergy the patient has (ie, a brief description of the type and severity):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>What insulin or additive the patient is allergic to and what other insulins should be avoided.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Where the culprit insulin or additive is likely to be encountered (especially protamine, which patients should be told is used to reverse the blood thinner heparin).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What alternative insulin the patient can safely take.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What treatments should be given if the patient has another reaction. (Eg, patients with anaphylaxis in the past should be provided with an <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> autoinjector and trained in proper use. Patients with urticaria should carry a dose of antihistamines and possibly glucocorticoids.) (See  <a class="medical medical_basics" href="/d/html/15917.html" rel="external">"Patient education: How to use an epinephrine autoinjector (The Basics)"</a> and  <a class="medical medical_patient" href="/d/html/365.html" rel="external">"Patient education: Using an epinephrine autoinjector (Beyond the Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15336.html" rel="external">"Patient education: Anaphylaxis (The Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H25138665"><span class="h4">Insulin desensitization</span><span class="headingEndMark"> — </span>Insulin desensitization should be considered when changing the insulin preparation is not feasible due to multiple sensitizations or when there have been difficulties stabilizing the blood sugar with the insulin preparations the patient does tolerate [<a href="#rid54">54,55</a>]. Most desensitizations have been performed with human insulins, although a few papers describe desensitization with insulin analogs [<a href="#rid56">56</a>].</p><p>Insulin desensitization is generally well tolerated and effective in most patients [<a href="#rid20">20,57</a>]. It can be used in patients with severe as well as mild symptoms [<a href="#rid58">58</a>]. The mechanism of insulin desensitization has not been fully elucidated, although the induction of anergy or depletion of specific T cells has been suggested, as well as the induction of T regulatory cells and the modulation of antibody production by cytokines [<a href="#rid59">59</a>]. Desensitization is also associated with a decrease in insulin-specific IgE titers and possibly an increase in IgG antibodies over time [<a href="#rid60">60</a>].</p><p>Most published insulin desensitization protocols consist of series of gradually increasing subcutaneous doses, although there are also reports of successful protocols using continuous subcutaneous infusion delivered through insulin pumps [<a href="#rid55">55,61-65</a>]. Continuous infusion has also been used on an emergency basis to manage diabetic ketoacidosis in a patient with insulin allergy [<a href="#rid66">66</a>]. In addition, cases of intravenous desensitization have been described [<a href="#rid67">67,68</a>].</p><p class="headingAnchor" id="H269028840"><span class="h5">Protocols</span><span class="headingEndMark"> — </span>The starting dose can be chosen based on the severity of the allergic symptoms. The author usually starts at 0.00001 international units and increases the dose 10-fold every 30 minutes up to 1 unit and then 2, 4, 8, 12, 16, and 20 international units. A protocol used in the author's clinic is provided (<a class="graphic graphic_table graphicRef88752" href="/d/graphic/88752.html" rel="external">table 4</a>). Premedications are not routinely given. The blood glucose is carefully monitored via fingersticks and stabilized by oral antidiabetics, if possible; another insulin preparation intravenously; or via an insulin pump. If necessary, blood glucose can be increased with oral or intravenous glucose.</p><p>In the author's experience, most patients can be successfully desensitized.</p><p class="bulletIndent1"><span class="glyph">●</span>If a local reaction occurs at the injection site during desensitization, we wait for it to subside (eg, while applying a cool pack) or treat the reaction, depending on the severity. Then, the same dose is repeated 30 minutes after the dose that caused the local reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a systemic reaction occurs, the protocol is suspended, and symptoms are treated. Once the symptoms have resolved, the protocol is restarted at one-half of the dose that caused the reaction.</p><p></p><p>Although most desensitizations are successful, failures and cases in which the effect was short lived have been reported [<a href="#rid11">11,69</a>]. In severe cases, desensitization has been combined with <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> [<a href="#rid54">54,70</a>].</p><p class="headingAnchor" id="H25138672"><span class="h4">Omalizumab and other options</span><span class="headingEndMark"> — </span>In selected cases and after desensitization, treatment with <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> has been tried, although it is not always effective [<a href="#rid71">71-73</a>]. One case report of a perceived insulin allergy refractory to desensitization described the use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> followed by <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil and omalizumab [<a href="#rid74">74</a>].</p><p>A rarely employed alternative is the transplantation of pancreas tissue and accompanying immunosuppression [<a href="#rid75">75,76</a>] or the transplantation of islet cells.</p><p class="headingAnchor" id="H4178521939"><span class="h2">Delayed reactions</span></p><p class="headingAnchor" id="H3774883373"><span class="h3">When to refer</span><span class="headingEndMark"> — </span>Diabetologists have experience in managing local insulin reactions. Delayed reactions are usually transient, resolving spontaneously within a few weeks with continuation of therapy. If the reactions do not improve after one or two months, referral to a dermatology or allergy specialist is appropriate to try to identify the cause of the reaction, as evaluation usually requires skin testing, patch testing, and/or skin biopsy. Once a cause is identified, an insulin preparation lacking this agent should be substituted, if possible.</p><p class="headingAnchor" id="H3761008143"><span class="h3">Testing</span><span class="headingEndMark"> — </span>Testing depends upon the type of delayed reaction.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induration and/or subcutaneous nodules</strong> – Evaluation involves one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Skin testing –</strong> A second reading of the skin testing sites after 24 hours is referred to as a "late reading." The presence of induration is considered a positive result, and the site is then examined again at 48 hours. The presence of induration at either time point is considered a positive reaction. Note that late readings of prick or intradermal tests are not standard protocol in the evaluation of immediate-type drug allergies, although the author and others have found this type of testing to be useful in identifying some forms of delayed insulin reactions [<a href="#rid5">5,23</a>]. The initial steps of skin testing are described above. (See <a class="local">'Skin testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biopsy –</strong> Punch biopsy of the affected skin is helpful to characterize the nature of the cellular infiltrate and determine if vasculitis is present [<a href="#rid77">77</a>]. Leukocytoclastic vasculitis responsive to systemic glucocorticoids was identified in one case [<a href="#rid78">78</a>]. Eosinophilic infiltrates have been described in delayed-type reactions [<a href="#rid79">79</a>] and in reactions after intradermal testing [<a href="#rid6">6</a>]. Granulomatous reactions have also been described and attributed to IgG antibodies directed against insulin, which form immune complexes that precipitate in the tissue [<a href="#rid80">80,81</a>]. These reactions may represent a localized Arthus reaction [<a href="#rid77">77</a>]. The binding of this antibody might also affect the kinetics of insulin action. Biopsy can also exclude other causes of subcutaneous induration or nodules.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory tests –</strong> Other laboratory tests may provide additional information, although they are not necessary for the diagnosis. Anti-insulin IgG1 antibodies have been reported to be elevated in patients with local hypersensitivity reactions compared with controls. However, it should be noted that anti-insulin IgG antibodies are commonly found in insulin-treated patients and are not necessarily associated with clinical symptoms [<a href="#rid82">82,83</a>]. Lymphocyte transformation tests, where available, can help assess the T cell response to specific drugs [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythematous or eczematous skin changes or exanthema</strong> – With this presentation, it is important first to make sure that the patient does not have other dermatologic conditions, such as atopic dermatitis. Exanthema can also be associated with infectious disease or reactions to other drugs (eg, antibiotics). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Patch testing is appropriate for the evaluation of eczematous local reactions or exanthema. Cresol reactions have been demonstrated with patch testing [<a href="#rid3">3</a>]. One report used a solution of medium-containing 3 mg/mL metacresol and glycerol in a Finn chamber for patch testing and tested glycerol alone in parallel [<a href="#rid85">85</a>]. A more general discussion of patch testing is found separately. (See  <a class="medical medical_review" href="/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p></p><p class="bulletIndent1">Exanthema have been attributed to delayed-type hypersensitivity reactions involving predominantly T cells (type IVc) or eosinophils (type IVb) [<a href="#rid3">3</a>]. Some patients may additionally experience systemic symptoms, including maculopapular eruptions, headache, nausea, or diarrhea [<a href="#rid3">3</a>]. Systemic symptoms have been attributed to additives within the insulin preparations, such as cresol (or metacresol), protamine, and zinc [<a href="#rid3">3,5,29,51,85-87</a>]. Crystalline zinc solutions can alter immunogenicity by changing the structure of the insulin B chain [<a href="#rid84">84,88</a>]. Protamine may also act as adjuvant [<a href="#rid89">89</a>]. Other reports mentioned additional potential contact allergens in insulin, including parabens, phenol, nickel, and isophane, but specific cases of hypersensitivity to these agents in insulin were not cited [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Materials from the catheter pump and application devices can also cause such hypersensitivity reactions [<a href="#rid90">90-95</a>]. Specifically, patients with diabetes have developed contact dermatitis to acrylates in the plastic catheters of infusion sets [<a href="#rid90">90,93</a>] and in the "butterfly" glue (Loctite [brand name]) [<a href="#rid92">92</a>].</p><p></p><p class="headingAnchor" id="H2601671520"><span class="h3">Treatment of confirmed allergy</span><span class="headingEndMark"> — </span>If evaluation identifies a specific allergen as causing a reaction, then avoidance is the primary management. Insulin preparations lacking the culprit component should be used instead. In one report of a patient with documented metacresol hypersensitivity, a short-acting insulin preparation containing methylparabens instead of metacresol was obtained from the manufacturer [<a href="#rid85">85</a>]. This product was not commercially available but was provided for the patient once the hypersensitivity was documented.</p><p class="headingAnchor" id="H2550952963"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109237.html" rel="external">"Society guideline links: Drug allergy and hypersensitivity"</a>.)</p><p class="headingAnchor" id="H25138980"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity reactions to human insulins are rare –</strong> Hypersensitivity reactions to human insulins and insulin analogs are uncommon. These reactions may be caused by the insulin itself or by additives within the preparation and can occur in all age groups and in patients with either type 1 or type 2 diabetes. In most cases, skin changes that are suspected to be a manifestation of insulin hypersensitivity have other causes, such as injection-site irritation or a separate dermatologic condition. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactions can be immediate or delayed –</strong> Hypersensitivity reactions are categorized as immediate or delayed. Clinical history should focus on the rapidity with which the signs and symptoms develop after injection to distinguish immediate from delayed reactions and on the presence or absence of systemic symptoms. (See <a class="local">'Types of hypersensitivity reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immediate reactions generally develop within one hour after an injection and often much more quickly. These rare reactions range from local erythema or a pruritic wheal at the injection site to systemic anaphylaxis that may involve generalized urticaria, pruritus, angioedema, or hypotension (<a class="graphic graphic_table graphicRef58836" href="/d/graphic/58836.html" rel="external">table 1</a>). They are believed to be immunoglobulin E (IgE) mediated, type I immunologic reactions to insulin or to an additive, such as protamine (<a class="graphic graphic_table graphicRef80466" href="/d/graphic/80466.html" rel="external">table 2A</a> and <a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>). Immediate reactions tend to worsen over time and must be actively evaluated and managed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed reactions develop later than one hour and typically several hours to one or two days later. Common presentations include eczematous skin changes or induration or nodules at the sites of injection. Delayed reactions usually resolve spontaneously with time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate reactions –</strong> Initial interventions in the patient suspected of having immediate reactions to insulin preparations depend upon the severity of the reaction. Patients who have experienced anaphylaxis and require ongoing insulin therapy should be admitted to the hospital urgently for multidisciplinary management. For less severe reactions, options include empirically changing insulin preparations and use of a glucagon-like peptide 1 (GLP-1) receptor agonist, symptomatic treatment with antihistamines or glucocorticoids (if the reaction is mild and localized), and discontinuing insulin therapy (feasible in some patients with type 2 diabetes). (See <a class="local">'Initial Interventions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of an immediate hypersensitivity reaction to insulin is based upon a suggestive clinical history, the demonstration of immediate sensitization to insulin (using skin prick/intracutaneous testing and/or IgE immunoassays) or additive (<a class="graphic graphic_form graphicRef89388" href="/d/graphic/89388.html" rel="external">form 1</a>), and exclusion of other causes of the symptoms. Referral to an allergy expert is indicated. An evaluation for immediate hypersensitivity should be performed if the patient's reaction has any features of an immediate reaction. (See <a class="local">'Referral for allergy evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If an immediate allergy is confirmed to a specific insulin or additive, the allergy should be documented and explained to the patient. The causative allergen can be avoided by choosing a different preparation in some cases (<a class="graphic graphic_table graphicRef91420" href="/d/graphic/91420.html" rel="external">table 2B</a>). In patients for whom no alternative preparation can be identified or for those who cannot achieve adequate control of blood sugars using alternative insulins, we suggest desensitization to the desired insulin (<a class="graphic graphic_table graphicRef88752" href="/d/graphic/88752.html" rel="external">table 4</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Case reports have described the use of anti-IgE therapy, pancreatic transplant, and immunosuppressants in complicated cases. (See <a class="local">'Management of confirmed allergy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed reactions –</strong> Delayed reactions at the site of insulin injection are usually transient, resolving spontaneously within a few weeks with continuation of therapy. Initial measures are intended to minimize symptoms and include topical therapies or oral antihistamines. If the reactions do not improve after a couple of months, referral to an allergy or dermatology expert is appropriate to try to identify the cause of the reaction, as evaluation usually requires patch testing, skin testing with delayed readings, and/or skin biopsy (See <a class="local">'For delayed reactions'</a> above and <a class="local">'Delayed reactions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fernández L, Duque S, Montalbán C, Bartolomé B. Allergy to human insulin. Allergy 2003; 58:1317.</a></li><li><a class="nounderline abstract_t">Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev 2007; 23:348.</a></li><li><a class="nounderline abstract_t">Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol 2011; 29:300.</a></li><li><a class="nounderline abstract_t">Garg SK, Wernicke-Panten K, Wardecki M, et al. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther 2020; 22:85.</a></li><li><a class="nounderline abstract_t">Bodtger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med 2005; 22:102.</a></li><li><a class="nounderline abstract_t">Sola-Gazagnes A, Pecquet C, Berré S, et al. Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study. Diabetologia 2022; 65:1278.</a></li><li><a class="nounderline abstract_t">Qureshi K, Naeem N, Tariq J, et al. New-Onset Insulin Allergy After COVID-19 Infection in an Insulin-Dependent Type-2 Diabetic Patient: A Rare Complication. Cureus 2021; 13:e17879.</a></li><li><a class="nounderline abstract_t">Komamura H, Kawana Y, Imai J, Katagiri H. Insulin allergy manifesting soon after COVID-19 vaccination (BNT162b2). J Diabetes Investig 2023; 14:498.</a></li><li><a class="nounderline abstract_t">Hasselmann C, Pecquet C, Bismuth E, et al. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy. Diabetes Metab 2013; 39:174.</a></li><li class="breakAll">Pichler WJ. Drug hypersensitivity reactions: Classification and relationship to T-cell activation. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger, Basel 2007. p.168.</li><li><a class="nounderline abstract_t">Chng HH, Leong KP, Loh KC. Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization. Allergy 1995; 50:984.</a></li><li><a class="nounderline abstract_t">Gonzalo MA, De Argila D, Revenga F, et al. Cutaneous allergy to human (recombinant DNA) insulin. Allergy 1998; 53:106.</a></li><li><a class="nounderline abstract_t">Wessbecher R, Kiehn M, Stoffel E, Moll I. Management of insulin allergy. Allergy 2001; 56:919.</a></li><li><a class="nounderline abstract_t">Newman AC, Nasser S, Dinneen SF. Insulin allergy with 'light-up' reaction. Diabet Med 2019; 36:1709.</a></li><li><a class="nounderline abstract_t">Scheer BG, Sitz KV. Suspected insulin anaphylaxis and literature review. J Ark Med Soc 2001; 97:311.</a></li><li><a class="nounderline abstract_t">Blanco C, Castillo R, Quiralte J, et al. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Allergy 1996; 51:421.</a></li><li><a class="nounderline abstract_t">Chu YQ, Cai LJ, Jiang DC, et al. Allergic shock and death associated with protamine administration in a diabetic patient. Clin Ther 2010; 32:1729.</a></li><li><a class="nounderline abstract_t">Kaya A, Gungor K, Karakose S. Severe anaphylactic reaction to human insulin in a diabetic patient. J Diabetes Complications 2007; 21:124.</a></li><li><a class="nounderline abstract_t">Velcovsky HG, Federlin KF. Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 1982; 5 Suppl 2:126.</a></li><li><a class="nounderline abstract_t">Heinzerling L, Raile K, Rochlitz H, et al. Insulin allergy: clinical manifestations and management strategies. Allergy 2008; 63:148.</a></li><li><a class="nounderline abstract_t">Patterson R, Lucena G, Metz R, Roberts M. Reaginic antibody against insulin: demonstra- tion of antigenic distinction between native and extracted insulin. J Immunol 1969; 103:1061.</a></li><li><a class="nounderline abstract_t">Alvarez-Thull L, Rosenwasser LJ, Brodie TD. Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin. Ann Allergy Asthma Immunol 1996; 76:253.</a></li><li><a class="nounderline abstract_t">Lee AY, Chey WY, Choi J, Jeon JS. Insulin-induced drug eruptions and reliability of skin tests. Acta Derm Venereol 2002; 82:114.</a></li><li><a class="nounderline abstract_t">Jaeger C, Eckhard M, Brendel MD, Bretzel RG. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy. Exp Clin Endocrinol Diabetes 2004; 112:416.</a></li><li><a class="nounderline abstract_t">Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol 2007; 8:21.</a></li><li><a class="nounderline abstract_t">Breznik V, Kokol R, Luzar B, Miljković J. Insulin-induced localized lipoatrophy. Acta Dermatovenerol Alp Pannonica Adriat 2013; 22:83.</a></li><li><a class="nounderline abstract_t">Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013; 39:445.</a></li><li><a class="nounderline abstract_t">Famulla S, Hövelmann U, Fischer A, et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care 2016; 39:1486.</a></li><li><a class="nounderline abstract_t">Wheeler BJ, Taylor BJ. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report. J Med Case Rep 2012; 6:263.</a></li><li><a class="nounderline abstract_t">Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997; 20:1357.</a></li><li><a class="nounderline abstract_t">Airaghi L, Lorini M, Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diabetes Care 2001; 24:2000.</a></li><li><a class="nounderline abstract_t">Moriyama H, Nagata M, Fujihira K, et al. Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. Diabetes Care 2001; 24:411.</a></li><li><a class="nounderline abstract_t">Pánczél P, Hosszúfalusi N, Horváth MM, Horváth A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000; 55:409.</a></li><li><a class="nounderline abstract_t">Takata H, Kumon Y, Osaki F, et al. The human insulin analogue aspart is not the almighty solution for insulin allergy. Diabetes Care 2003; 26:253.</a></li><li><a class="nounderline abstract_t">Barranco R, Herrero T, Tornero P, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58:536.</a></li><li><a class="nounderline abstract_t">Pradhan R, Montastruc F, Rousseau V, et al. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes Endocrinol 2020; 8:13.</a></li><li><a class="nounderline abstract_t">Ornelas C, Caiado J, Lopes A, et al. Anaphylaxis to Long-Acting Release Exenatide. J Investig Allergol Clin Immunol 2018; 28:332.</a></li><li><a class="nounderline abstract_t">Pérez E, Martínez-Tadeo J, Callero A, et al. A case report of allergy to exenatide. J Allergy Clin Immunol Pract 2014; 2:822.</a></li><li><a class="nounderline abstract_t">Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 Suppl 3:155.</a></li><li><a class="nounderline abstract_t">Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4:189.</a></li><li><a class="nounderline abstract_t">Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung 1999; 28:418.</a></li><li><a class="nounderline abstract_t">Stewart WJ, McSweeney SM, Kellett MA, et al. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation 1984; 70:788.</a></li><li><a class="nounderline abstract_t">Sharath MD, Metzger WJ, Richerson HB, et al. Protamine-induced fatal anaphylaxis. Prevalence of antiprotamine immunoglobulin E antibody. J Thorac Cardiovasc Surg 1985; 90:86.</a></li><li><a class="nounderline abstract_t">Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg 1986; 65:739.</a></li><li><a class="nounderline abstract_t">Weiss ME, Adkinson NF Jr. Allergy to protamine. Clin Rev Allergy 1991; 9:339.</a></li><li><a class="nounderline abstract_t">Weiss ME, Chatham F, Kagey-Sobotka A, Adkinson NF Jr. Serial immunological investigations in a patient who had a life-threatening reaction to intravenous protamine. Clin Exp Allergy 1990; 20:713.</a></li><li><a class="nounderline abstract_t">Roest MA, Shaw S, Orton DI. Insulin-injection-site reactions associated with type I latex allergy. N Engl J Med 2003; 348:265.</a></li><li><a class="nounderline abstract_t">Danne T, Niggemann B, Weber B, Wahn U. Prevalence of latex-specific IgE antibodies in atopic and nonatopic children with type I diabetes. Diabetes Care 1997; 20:476.</a></li><li><a class="nounderline abstract_t">Heinzerling L, Frew AJ, Bindslev-Jensen C, et al. Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. Allergy 2005; 60:1287.</a></li><li><a class="nounderline abstract_t">Heinzerling L, Mari A, Bergmann KC, et al. The skin prick test - European standards. Clin Transl Allergy 2013; 3:3.</a></li><li><a class="nounderline abstract_t">deShazo RD, Mather P, Grant W, et al. Evaluation of patients with local reactions to insulin with skin tests and in vitro techniques. Diabetes Care 1987; 10:330.</a></li><li><a class="nounderline abstract_t">Fujishiro M, Izumida Y, Takemiya S, et al. A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide. Diabet Med 2016; 33:e26.</a></li><li><a class="nounderline abstract_t">Mastrorilli C, Rizzuti L, Cangelosi AM, et al. Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol 2017; 30:174.</a></li><li><a class="nounderline abstract_t">Yokoyama H, Fukumoto S, Koyama H, et al. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Pract 2003; 61:161.</a></li><li><a class="nounderline abstract_t">Moyes V, Driver R, Croom A, et al. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006; 23:204.</a></li><li><a class="nounderline abstract_t">Wu P, Ji C, Wang M, et al. Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine. Ann Endocrinol (Paris) 2013; 74:56.</a></li><li><a class="nounderline abstract_t">Yuan T, Zhao W, Wang L, et al. Continuous Subcutaneous Insulin Infusion as an Effective Method of Desensitization Therapy for Diabetic Patients with Insulin Allergy: A 4-year Single-center Experience. Clin Ther 2016; 38:2489.</a></li><li><a class="nounderline abstract_t">Eguíluz-Gracia I, Rodríguez-Alvarez M, Cimarra-Alvarez M, et al. Desensitization for insulin allergy: a useful treatment also for local forms. J Investig Allergol Clin Immunol 2012; 22:215.</a></li><li><a class="nounderline abstract_t">Jutel M, Akdis M, Budak F, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205.</a></li><li><a class="nounderline abstract_t">Mattson JR, Patterson R, Roberts M. Insulin therapy in patients with systemic insulin allergy. Arch Intern Med 1975; 135:818.</a></li><li><a class="nounderline abstract_t">Näf S, Esmatjes E, Recasens M, et al. Continuous subcutaneous insulin infusion to resolve an allergy to human insulin. Diabetes Care 2002; 25:634.</a></li><li><a class="nounderline abstract_t">Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997; 36:575.</a></li><li><a class="nounderline abstract_t">Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med 2001; 18:515.</a></li><li><a class="nounderline abstract_t">Sola-Gazagnes A, Pecquet C, Radermecker R, et al. Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin. Diabetes Care 2003; 26:2961.</a></li><li><a class="nounderline abstract_t">Fujikawa T, Imbe H, Date M, et al. Severe insulin allergy successfully treated with continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2012; 97:e31.</a></li><li><a class="nounderline abstract_t">Nguyen AD, Luong CQ, Chu HC, et al. Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report. BMC Endocr Disord 2019; 19:121.</a></li><li><a class="nounderline abstract_t">Asai M, Yoshida M, Miura Y. Immunologic tolerance to intravenously injected insulin. N Engl J Med 2006; 354:307.</a></li><li><a class="nounderline abstract_t">Shuster S, Borici-Mazi R, Awad S, Houlden RL. RAPID DESENSITIZATION WITH INTRAVENOUS INSULIN IN A PATIENT WITH DIABETIC KETOACIDOSIS AND INSULIN ALLERGY. AACE Clin Case Rep 2020; 6:e147.</a></li><li><a class="nounderline abstract_t">Frigerio C, Aubry M, Gomez F, et al. Desensitization-resistant insulin allergy. Allergy 1997; 52:238.</a></li><li><a class="nounderline abstract_t">Grant W, deShazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes Care 1986; 9:318.</a></li><li><a class="nounderline abstract_t">Cavelti-Weder C, Muggli B, Keller C, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care 2012; 35:e41.</a></li><li><a class="nounderline abstract_t">Mishra S, Connors L, Tugwell B. Role of omalizumab in insulin hypersensitivity: a case report and review of the literature. Diabet Med 2018; 35:663.</a></li><li><a class="nounderline abstract_t">Wong S. Exacerbation of asthma after initiation of insulin therapy in a patient treated with omalizumab. Ann Allergy Asthma Immunol 2009; 102(suppl):A78.</a></li><li><a class="nounderline abstract_t">Yong PF, Malik R, Arif S, et al. Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 2009; 360:1045.</a></li><li><a class="nounderline abstract_t">Léonet J, Malaise J, Goffin E, et al. Solitary pancreas transplantation for life-threatening allergy to human insulin. Transpl Int 2006; 19:474.</a></li><li><a class="nounderline abstract_t">Léonet J, Malaise J, Squifflet JP. Refractory insulin allergy: pancreas transplantation or immunosuppressive therapy alone? Transpl Int 2010; 23:e39.</a></li><li><a class="nounderline abstract_t">deShazo RD, Boehm TM, Kumar D, et al. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol 1982; 69:229.</a></li><li><a class="nounderline abstract_t">Mandrup-Poulsen T, Mølvig J, Pildal J, et al. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia. Diabetes Care 2002; 25:242.</a></li><li><a class="nounderline abstract_t">Zhang J, Chen Y, Wang J, et al. The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis. Nagoya J Med Sci 2021; 83:343.</a></li><li><a class="nounderline abstract_t">Silva ME, Mendes MJ, Ursich MJ, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient. Diabetes Res Clin Pract 1997; 36:67.</a></li><li><a class="nounderline abstract_t">Darmon P, Castera V, Koeppel MC, et al. Type III allergy to insulin detemir. Diabetes Care 2005; 28:2980.</a></li><li><a class="nounderline abstract_t">Fineberg SE, Kawabata TT, Finco-Kent D, et al. Immunological responses to exogenous insulin. Endocr Rev 2007; 28:625.</a></li><li><a class="nounderline abstract_t">Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004; 251 Suppl 2:II4.</a></li><li><a class="nounderline abstract_t">Ratner RE, Phillips TM, Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 1990; 39:728.</a></li><li><a class="nounderline abstract_t">Clerx V, Van Den Keybus C, Kochuyt A, Goossens A. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis 2003; 48:162.</a></li><li><a class="nounderline abstract_t">Feinglos MN, Jegasothy BV. "Insulin" allergy due to zinc. Lancet 1979; 1:122.</a></li><li><a class="nounderline abstract_t">Raap U, Liekenbröcker T, Kapp A, Wedi B. Delayed-type hypersensitivity to protamine as a complication of insulin therapy. Contact Dermatitis 2005; 53:57.</a></li><li><a class="nounderline abstract_t">Yip CM, Brader ML, DeFelippis MR, Ward MD. Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure. Biophys J 1998; 74:2199.</a></li><li><a class="nounderline abstract_t">Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2:283.</a></li><li><a class="nounderline abstract_t">Saccabusi S, Boatto G, Asproni B, Pau A. Sensitization to methyl methacrylate in the plastic catheter of an insulin pump infusion set. Contact Dermatitis 2001; 45:47.</a></li><li><a class="nounderline abstract_t">Corazza M, Borghi A, Sarno O, et al. Antecubital allergic contact dermatitis from intravenous iron infusion: a possible etiological role of nickel. Eur J Dermatol 2011; 21:284.</a></li><li><a class="nounderline abstract_t">Jolanki R, Kanerva L, Estlander T, et al. Allergic contact dermatitis from phenoxyethoxy ethylacrylates in optical fiber coating, and glue in an insulin pump set. Contact Dermatitis 2001; 45:36.</a></li><li><a class="nounderline abstract_t">van den Hove J, Jacobs MC, Tennstedt D, Lachapelle JM. Allergic contact dermatitis from acrylates in insulin pump infusion sets. Contact Dermatitis 1996; 35:108.</a></li><li><a class="nounderline abstract_t">Busschots AM, Meuleman V, Poesen N, Dooms-Goossens A. Contact allergy to components of glue in insulin pump infusion sets. Contact Dermatitis 1995; 33:205.</a></li><li><a class="nounderline abstract_t">Corazza M, Maranini C, Aleotti A, Virgili A. Nickel contact dermatitis due to the needle of an infusion pump, confirmed by microanalysis. Contact Dermatitis 1998; 39:144.</a></li></ol></div><div id="topicVersionRevision">Topic 88482 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616113" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Allergy to human insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17216593" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496738" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31804851" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606700" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A rational clinical approach to suspected insulin allergy: status after five years and 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35505238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34660078" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : New-Onset Insulin Allergy After COVID-19 Infection in an Insulin-Dependent Type-2 Diabetic Patient: A Rare Complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36562465" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Insulin allergy manifesting soon after COVID-19 vaccination (BNT162b2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23206896" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23206896" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834829" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary systemic allergy to human insulin: recurrence of generalized urticaria after successful desensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9491241" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cutaneous allergy to human (recombinant DNA) insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551264" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Management of insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31454104" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Insulin allergy with 'light-up' reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11233502" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Suspected insulin anaphylaxis and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8837667" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21194595" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Allergic shock and death associated with protamine administration in a diabetic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17331861" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe anaphylactic reaction to human insulin in a diabetic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6765522" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin (recombinant DNA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186805" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Insulin allergy: clinical manifestations and management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4187114" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Reaginic antibody against insulin: demonstra- tion of antigenic distinction between native and extracted insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634879" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systemic allergy to endogenous insulin during therapy with recombinant DNA (rDNA) insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12125938" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Insulin-induced drug eruptions and reliability of skin tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15372360" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298103" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336944" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Insulin-induced localized lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886784" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27411698" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937994" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9283778" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lispro analog for treatment of generalized allergy to human insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679473" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The insulin analog aspart: a safe alternative in insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213905" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782533" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Advantage of insulin lispro in suspected insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12502700" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The human insulin analogue aspart is not the almighty solution for insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12757463" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Systemic allergic reaction by a human insulin analog.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806579" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30350785" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anaphylaxis to Long-Acting Release Exenatide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439386" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A case report of allergy to exenatide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299472" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Immunogenicity and allergenic potential of animal and human insulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2421863" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580216" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Allergy to protamine sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6488493" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892171" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Protamine-induced fatal anaphylaxis. Prevalence of antiprotamine immunoglobulin E antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2424341" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1782626" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Allergy to protamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1707334" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serial immunological investigations in a patient who had a life-threatening reaction to intravenous protamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529475" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Insulin-injection-site reactions associated with type I latex allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096963" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence of latex-specific IgE antibodies in atopic and nonatopic children with type I diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134996" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369181" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The skin prick test - European standards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2954799" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of patients with local reactions to insulin with skin tests and in vitro techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26485621" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28368217" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-acting insulin allergy in a diabetic child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12965105" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433720" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23351561" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glargine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27793354" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Continuous Subcutaneous Insulin Infusion as an Effective Method of Desensitization Therapy for Diabetic Patients with Insulin Allergy: A 4-year Single-center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22697012" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Desensitization for insulin allergy: a useful treatment also for local forms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12731045" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1130927" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Insulin therapy in patients with systemic insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11874967" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Continuous subcutaneous insulin infusion to resolve an allergy to human insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9260776" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472474" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Localized insulin allergy treated with continuous subcutaneous insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14514615" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful treatment of insulin allergy in a type 1 diabetic patient by means of constant subcutaneous pump infusion of insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22609054" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Severe insulin allergy successfully treated with continuous subcutaneous insulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31711488" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421379" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Immunologic tolerance to intravenously injected insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32671215" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : RAPID DESENSITIZATION WITH INTRAVENOUS INSULIN IN A PATIENT WITH DIABETIC KETOACIDOSIS AND INSULIN ALLERGY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105538" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Desensitization-resistant insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732003" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22619293" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29381818" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Role of omalizumab in insulin hypersensitivity: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Exacerbation of asthma after initiation of insulin therapy in a patient treated with omalizumab</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19264698" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rituximab and omalizumab in severe, refractory insulin allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16771868" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Solitary pancreas transplantation for life-threatening allergy to human insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20230538" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Refractory insulin allergy: pancreas transplantation or immunosuppressive therapy alone?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7035526" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772924" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type 1 diabetes and essential thrombocytemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34239182" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9229189" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16306568" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Type III allergy to insulin detemir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785428" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Immunological responses to exogenous insulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15264106" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Immunogenicity of recombinant human proteins: causes and consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189764" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755733" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Drug intolerance reaction to insulin therapy caused by metacresol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/84149" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : "Insulin" allergy due to zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982236" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Delayed-type hypersensitivity to protamine as a complication of insulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591647" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/510122" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422275" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sensitization to methyl methacrylate in the plastic catheter of an insulin pump infusion set.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324789" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Antecubital allergic contact dermatitis from intravenous iron infusion: a possible etiological role of nickel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422266" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Allergic contact dermatitis from phenoxyethoxy ethylacrylates in optical fiber coating, and glue in an insulin pump set.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917834" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Allergic contact dermatitis from acrylates in insulin pump infusion sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565472" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Contact allergy to components of glue in insulin pump infusion sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9772000" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nickel contact dermatitis due to the needle of an infusion pump, confirmed by microanalysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
